Meet Hepatologist Michael Schilsky, MD

Why It Matters

Advances in liver transplant protocols and emerging gene therapies improve patient outcomes while conserving limited donor organs, reshaping the economics and ethics of hepatic care.

Key Takeaways

• Liver transplantation evolved since 1970s into standard therapy.
• Transplants treat acute failure and chronic liver disease lacking meds.
• Multidisciplinary teams enable detailed patient assessment and care.
• Non‑transplant interventions restore function, freeing organs for others.
• Future gene therapies may halt disease, reducing transplant need.

Summary

The video features hepatologist Michael Schilsky, MD, outlining how liver transplantation has progressed from a pioneering procedure in the 1970s to a routine component of modern hepatology. He explains that transplants now address both severe acute liver failure and, more commonly, chronic liver disease when existing medical therapies fall short.

Schilsky emphasizes the importance of a multidisciplinary approach—surgical, medical, and consulting teams collaborate to evaluate each patient comprehensively, guiding them through the complex transplant process. He also highlights that many patients can avoid transplantation altogether through advanced medical management, thereby preserving scarce donor organs for those with no alternatives.

The physician notes his personal satisfaction in restoring liver function without surgery, quoting that such successes “make more organs available for those who need it.” He looks ahead to emerging gene‑editing and gene‑therapy techniques that could interrupt disease progression, potentially eliminating the need for transplantation in a subset of patients.

These developments signal a shift toward less invasive, more personalized liver care, improving patient quality of life while easing the pressure on organ donation systems. The prospect of gene‑based cures could further transform the therapeutic landscape, reducing long‑term healthcare costs and expanding treatment options.

Original Description

For more information on Dr. Schilsky or #YaleMedicine, visit: https://www.yalemedicine.org/specialists/michael-schilsky.

Michael Schilsky, MD, is the medical director of Adult Liver Transplant at Yale-New Haven Transplantation Center. He is an internationally recognized expert in Wilson disease, a rare genetic disorder in which excessive amounts of copper accumulate in the body. Dr. Schilsky says he was drawn to the study and treatment of Wilson disease because of its complexity, and he is optimistic about the growing promise of new treatments that can help patients with this difficult medical condition. “Wilson disease can be hard to diagnose as it can present with a constellation of symptoms, but once considered we have great tools now to establish the diagnosis and treat this disorder,” he says. “The future is very bright. We hope to have a cure someday, perhaps by genetic therapy. In the meantime, new innovations and medications being tested in clinical trials are truly helping patients.” An advisor to the Wilson Disease Association, Dr. Schilsky helped write guidelines for the diagnosis and treatment of the disorder for both the American Association for the Study of Liver Disease and the European Association for Liver Disease. Here in the Northeast, Yale is the only Center of Excellence designated by the Wilson Disease Association. We are one of a limited number of sites worldwide to participate in a clinical trial for a promising new therapy for Wilson disease, an oral medication known as WTX101. Left untreated, Wilson disease can cause advanced liver disease or acute liver failure. Dr. Schilsky specializes in managing these challenging cases, including those caused by other metabolic liver diseases. If a liver transplant is required (these are performed at Yale-New Haven Hospital) Dr. Schilsky cares for patients both before and after the surgery. Dr. Schilsky is also a professor of medicine (digestive diseases) and surgery (transplant and immunology) at Yale School of Medicine.